Point72 Asset Management
ESPR

Point72 Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Point72 Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,689,372
Closed -$4.63M – 4176
2026
Q1 		$4.63M Buy
+1,689,372
New +$5.35M 0.01% 1758
2025
Q4 		– Sell
-2,201
Closed -$5.83K – 3978
2025
Q3 		$5.83K Buy
+2,201
New +$4.26K ﹤0.01% 2259
2024
Q3 		– Sell
-67,070
Closed -$149K – 2087
2024
Q2 		$149K Buy
67,070
+51,000
+317% +$120K ﹤0.01% 1662
2024
Q1 		$43.1K Buy
16,070
+11,270
+235% +$27.4K ﹤0.01% 2070
2023
Q4 		$14.4K Sell
4,800
-3,093,052
-100% -$4.01M ﹤0.01% 2053
2023
Q3 		$3.04M Sell
3,097,852
-1,877,148
-38% -$2.72M 0.01% 1033
2023
Q2 		$6.92M Buy
4,975,000
+1,375,000
+38% +$1.92M 0.02% 698
2023
Q1 		$5.72M Buy
3,600,000
+1,323,000
+58% +$6.83M 0.02% 718
2022
Q4 		$14.2M Sell
2,277,000
-511,300
-18% -$3.66M 0.05% 437
2022
Q3 		$18.7M Buy
2,788,300
+1,725,204
+162% +$11.8M 0.07% 346
2022
Q2 		$6.76M Buy
+1,063,096
New +$6.03M 0.03% 622
2021
Q2 		– Sell
-648,200
Closed -$18.2M – 1025
2021
Q1 		$18.2M Buy
+648,200
New +$19.1M 0.08% 283
2020
Q1 		– Sell
-4,800
Closed -$286K – 866
2019
Q4 		$286K Sell
4,800
-414,590
-99% -$18.6M ﹤0.01% 821
2019
Q3 		$15.4M Buy
419,390
+352,617
+528% +$14M 0.09% 264
2019
Q2 		$3.11M Sell
66,773
-150,327
-69% -$7.06M 0.02% 589
2019
Q1 		$8.72M Buy
+217,100
New +$9.74M 0.04% 433
2018
Q4 		– Sell
-507,300
Closed -$22.5M – 1032
2018
Q3 		$22.5M Buy
507,300
+143,200
+39% +$6.57M 0.09% 276
2018
Q2 		$14.3M Buy
+364,100
New +$18.4M 0.06% 363
2015
Q4 		– Sell
-77,000
Closed -$1.82M – 721
2015
Q3 		$1.82M Buy
77,000
+38,200
+98% +$2.4M 0.01% 575
2015
Q2 		$3.17M Buy
+38,800
New +$3.8M 0.02% 520
2015
Q1 		– Sell
-10,700
Closed -$433K – 714
2014
Q4 		$433K Buy
+10,700
New +$328K ﹤0.01% 618

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Point72 Asset Management's ESPR Position: Q2 2026 in Review

Point72 Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 1,689,372 shares — an estimated $4.63M sold.

Point72 Asset Management first reported a position in ESPR in Q4 2014 and held it in 21 quarters. The position peaked at $22.5M in Q3 2018. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Point72 Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,689,372 Esperion Therapeutics shares in Q2 2026, an estimated $4.63M.
  • Point72 Asset Management first reported a position in Esperion Therapeutics in Q4 2014 and held it in 21 quarters.
  • Point72 Asset Management's Esperion Therapeutics position peaked at $22.5M in Q3 2018.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.